Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

HylaPharm

HylaPharm?uq=PEM9b6PF
2010 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Angel LATEST DEAL TYPE
$800K LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of targeted cancer therapies and cancer drugs. The company specializes in the research and development of new cancer drugs for chemotherapeutic use.

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 2029 Becker Drive
  • Suite 285
  • Lawrence, KS 66047
  • United States

+1 (785) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore HylaPharm’s full profile, request a free trial.

HylaPharm Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 01-Oct-2015 $800K 00.00 Completed Generating Revenue
2. Angel (individual) 16-Dec-2013 00000 00000 Completed Startup
1. Grant 22-Jan-2013 $200K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

HylaPharm Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Kansas Bioscience Authority Government Minority 000 0000 000000 0

HylaPharm Executive Team (3)

Name Title Board
Seat
Contact
Info
Daniel Aires MD Chief Executive Officer, President and Board Member
Craig Paddock Chief Financial Officer & Board Member
Laird Forrest Ph.D Founder, Chief Technology Officer and Board Member

HylaPharm Board Members (1)

Name Representing Role Since Contact
Info
Craig Paddock HylaPharm Chief Financial Officer & Board Member 000 0000